Calliditas Therapeutics Valuation
Is CALTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CALTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CALTX (SEK205.6) is trading below our estimate of fair value (SEK4905.3)
Significantly Below Fair Value: CALTX is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CALTX?
Other financial metrics that can be useful for relative valuation.
| What is CALTX's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 11.03b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.6x |
| Enterprise Value/EBITDA | -27.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CALTX's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.3x | ||
SECARE Swedencare | 3.9x | 11.5% | SEK 9.4b |
CAMX Camurus | 19.3x | 32.3% | SEK 35.2b |
ORX Orexo | 1.1x | 15.6% | SEK 704.5m |
CLBIO Corline Biomedical | 8.9x | 68.2% | SEK 276.2m |
CALTX Calliditas Therapeutics | 8.4x | 29.7% | SEK 11.0b |
Price-To-Sales vs Peers: CALTX is expensive based on its Price-To-Sales Ratio (8.4x) compared to the peer average (8.3x).
Price to Earnings Ratio vs Industry
How does CALTX's PE Ratio compare vs other companies in the SE Pharmaceuticals Industry?
Price-To-Sales vs Industry: CALTX is good value based on its Price-To-Sales Ratio (8.4x) compared to the Swedish Pharmaceuticals industry average (10.7x).
Price to Sales Ratio vs Fair Ratio
What is CALTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.4x |
| Fair PS Ratio | 14.9x |
Price-To-Sales vs Fair Ratio: CALTX is good value based on its Price-To-Sales Ratio (8.4x) compared to the estimated Fair Price-To-Sales Ratio (14.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 205.60 | SEK 221.25 +7.6% | 15.3% | SEK 270.00 | SEK 177.00 | n/a | 4 |
| Jun ’25 | SEK 208.20 | SEK 208.00 -0.1% | 21.4% | SEK 270.00 | SEK 161.00 | n/a | 4 |
| May ’25 | SEK 110.00 | SEK 208.00 +89.1% | 21.4% | SEK 270.00 | SEK 161.00 | n/a | 4 |
| Apr ’25 | SEK 113.40 | SEK 208.00 +83.4% | 21.4% | SEK 270.00 | SEK 161.00 | n/a | 4 |
| Mar ’25 | SEK 111.40 | SEK 200.25 +79.8% | 26.1% | SEK 270.00 | SEK 140.00 | n/a | 4 |
| Feb ’25 | SEK 112.20 | SEK 202.75 +80.7% | 27.5% | SEK 280.00 | SEK 140.00 | n/a | 4 |
| Jan ’25 | SEK 127.10 | SEK 217.20 +70.9% | 26.5% | SEK 280.00 | SEK 140.00 | n/a | 5 |
| Dec ’24 | SEK 92.50 | SEK 217.20 +134.8% | 26.5% | SEK 280.00 | SEK 140.00 | n/a | 5 |
| Nov ’24 | SEK 90.85 | SEK 236.80 +160.6% | 20.5% | SEK 295.00 | SEK 154.00 | n/a | 5 |
| Oct ’24 | SEK 97.50 | SEK 236.80 +142.9% | 20.5% | SEK 295.00 | SEK 154.00 | n/a | 5 |
| Sep ’24 | SEK 91.55 | SEK 237.40 +159.3% | 20.0% | SEK 295.00 | SEK 157.00 | n/a | 5 |
| Aug ’24 | SEK 103.70 | SEK 246.40 +137.6% | 23.0% | SEK 310.00 | SEK 157.00 | n/a | 5 |
| Jul ’24 | SEK 86.70 | SEK 246.40 +184.2% | 23.0% | SEK 310.00 | SEK 157.00 | n/a | 5 |
| Jun ’24 | SEK 93.45 | SEK 246.40 +163.7% | 23.0% | SEK 310.00 | SEK 157.00 | SEK 208.20 | 5 |
| May ’24 | SEK 124.50 | SEK 259.80 +108.7% | 20.0% | SEK 315.00 | SEK 179.00 | SEK 110.00 | 5 |
| Apr ’24 | SEK 125.30 | SEK 259.80 +107.3% | 20.0% | SEK 315.00 | SEK 179.00 | SEK 113.40 | 5 |
| Mar ’24 | SEK 101.30 | SEK 255.80 +152.5% | 23.7% | SEK 315.00 | SEK 149.00 | SEK 111.40 | 5 |
| Feb ’24 | SEK 97.60 | SEK 246.80 +152.9% | 26.2% | SEK 305.00 | SEK 149.00 | SEK 112.20 | 5 |
| Jan ’24 | SEK 92.45 | SEK 236.00 +155.3% | 28.8% | SEK 305.00 | SEK 149.00 | SEK 127.10 | 4 |
| Dec ’23 | SEK 95.90 | SEK 233.50 +143.5% | 28.1% | SEK 300.00 | SEK 149.00 | SEK 92.50 | 4 |
| Nov ’23 | SEK 81.45 | SEK 229.50 +181.8% | 30.9% | SEK 300.00 | SEK 133.00 | SEK 90.85 | 4 |
| Oct ’23 | SEK 84.70 | SEK 229.50 +171.0% | 30.9% | SEK 300.00 | SEK 133.00 | SEK 97.50 | 4 |
| Sep ’23 | SEK 85.30 | SEK 242.67 +184.5% | 32.0% | SEK 300.00 | SEK 133.00 | SEK 91.55 | 3 |
| Aug ’23 | SEK 100.60 | SEK 241.67 +140.2% | 32.7% | SEK 300.00 | SEK 130.00 | SEK 103.70 | 3 |
| Jul ’23 | SEK 96.30 | SEK 241.67 +151.0% | 32.7% | SEK 300.00 | SEK 130.00 | SEK 86.70 | 3 |
| Jun ’23 | SEK 84.35 | SEK 212.50 +151.9% | 38.8% | SEK 295.00 | SEK 130.00 | SEK 93.45 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.